[go: up one dir, main page]

MX2009002228A - Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo. - Google Patents

Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo.

Info

Publication number
MX2009002228A
MX2009002228A MX2009002228A MX2009002228A MX2009002228A MX 2009002228 A MX2009002228 A MX 2009002228A MX 2009002228 A MX2009002228 A MX 2009002228A MX 2009002228 A MX2009002228 A MX 2009002228A MX 2009002228 A MX2009002228 A MX 2009002228A
Authority
MX
Mexico
Prior art keywords
treating
progression
compositions
methods
preventing glaucoma
Prior art date
Application number
MX2009002228A
Other languages
English (en)
Inventor
Stephen P Bartels
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of MX2009002228A publication Critical patent/MX2009002228A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición para tratar o prevenir glaucoma o su avance que comprende un agonista del receptor glucocorticoide disociado ("DIGRA"), su profármaco, su sal farmacéuticamente aceptable, o su éster farmacéuticamente aceptable. La composición puede comprender un agente anti-inflamatorio adicional y puede formularse para aplicación tópica, inyección, o implante. Se puede utilizar en combinación con otra terapia dirigida para reducir la presión intraocular.
MX2009002228A 2006-08-31 2007-08-24 Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo. MX2009002228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84143706P 2006-08-31 2006-08-31
PCT/US2007/076706 WO2008027796A2 (en) 2006-08-31 2007-08-24 Compositions and methods for treating or preventing glaucoma or progression thereof

Publications (1)

Publication Number Publication Date
MX2009002228A true MX2009002228A (es) 2009-04-17

Family

ID=39077201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002228A MX2009002228A (es) 2006-08-31 2007-08-24 Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo.

Country Status (16)

Country Link
US (1) US20080058373A1 (es)
EP (2) EP2056799B1 (es)
JP (1) JP2010502635A (es)
KR (1) KR20090050091A (es)
CN (1) CN101528208A (es)
AU (1) AU2007289373A1 (es)
BR (1) BRPI0716087A2 (es)
CA (1) CA2661607C (es)
DK (1) DK2056799T3 (es)
ES (1) ES2425178T3 (es)
MX (1) MX2009002228A (es)
PL (1) PL2056799T3 (es)
PT (1) PT2056799E (es)
SI (1) SI2056799T1 (es)
TW (1) TWI336701B (es)
WO (1) WO2008027796A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
US20090087443A1 (en) * 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
EP2214644B1 (en) * 2007-11-05 2013-03-20 Bausch & Lomb Incorporated Water-immiscible materials as vehicles for drug delivery
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
RU2473363C1 (ru) * 2012-02-24 2013-01-27 Илья Александрович Марков Противовирусное средство - глазные капли
KR20210119980A (ko) 2019-01-22 2021-10-06 아크리베스 바이오메디컬 게엠베하 손상된 피부 상처를 치료하기 위한 선택적 글루코코르티코이드 수용체 개질제

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
WO2000000194A1 (en) 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
CN1232365C (zh) 2001-07-03 2005-12-21 金井宏彰 箍环用金属线材及其制造方法和制造装置
DE60309829T2 (de) * 2002-01-14 2007-09-13 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoidmimetika, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische formulierungen und ihre verwendungen
KR101022977B1 (ko) * 2002-03-26 2011-03-18 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도
JP2005521717A (ja) * 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1521733B1 (en) * 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
MXPA05006872A (es) * 2003-01-03 2005-08-16 Boehringer Ingelheim Pharma Derivados de 1-propanol y 1-propilamina y su uso como ligandos glucocorticoides.
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004097410A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Screening methods for cataractogenic risk
US7235662B2 (en) * 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7537788B2 (en) * 2003-07-25 2009-05-26 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
CA2558019A1 (en) * 2004-03-22 2005-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
US7417056B2 (en) 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
EP2051710B1 (en) * 2006-08-07 2011-11-02 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases

Also Published As

Publication number Publication date
EP2056799B1 (en) 2013-07-31
ES2425178T3 (es) 2013-10-11
KR20090050091A (ko) 2009-05-19
PT2056799E (pt) 2013-11-06
CN101528208A (zh) 2009-09-09
TW200817378A (en) 2008-04-16
PL2056799T3 (pl) 2014-01-31
BRPI0716087A2 (pt) 2013-10-01
JP2010502635A (ja) 2010-01-28
US20080058373A1 (en) 2008-03-06
SI2056799T1 (sl) 2013-11-29
TWI336701B (en) 2011-02-01
CA2661607C (en) 2012-06-26
AU2007289373A1 (en) 2008-03-06
EP2397140A1 (en) 2011-12-21
CA2661607A1 (en) 2008-03-06
WO2008027796A3 (en) 2008-09-12
EP2056799A2 (en) 2009-05-13
DK2056799T3 (da) 2013-10-28
WO2008027796A2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2004089415A3 (en) COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
TW200626558A (en) Indazolone derivatives
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
WO2007135461A3 (en) Pharmaceutical compositions comprising implitapide and methods of using same
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
MX2009002228A (es) Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo.
WO2004006859A3 (en) Platinum compound
WO2008021729A3 (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
NZ577392A (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
WO2005032470A3 (en) Compositions and methods for treating burns
WO2008005686A8 (en) Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye
PL2061444T3 (pl) Kompozycje i sposoby leczenia, traktowania, kontrolowania, redukowania, łagodzenia lub zapobiegania alergii
MX2013014518A (es) Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio.
PL1976544T3 (pl) Sposób stosowania ekstraktu z guawy i kompozycja zawierająca ekstrakt z guawy
PT2190431E (pt) Composições compreendendo um agonista do recetor dos glucocorticoides dissociados para tratamento ou controlo de inflamação do segmento anterior
WO2008062475A3 (en) Pharmaceutical compositions of ursodiol
WO2008076804A3 (en) Method of treating intrauterine inflammation
WO2008076810A3 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
CY1114573T1 (el) Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη ή αποτροπη γλαυκωματος ή πορειας αυτου
WO2009075838A3 (en) Treatment of menorrhagia with aromatase inhibitor
UA90241C2 (ru) Противовоспалительная и болеутоляющая композиция для местного применения в участке опорно-двигательной системы животных
WO2007055890A3 (en) Co-administration of dehydroepiandrosterone (dhea) congeners and other active agents for treating cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal